The cellular basis of the impaired autologous mixed leukocyte reaction (AMLR) in patients with systemic lupus erythematosus (SLE) was investigated. Non-T cells from normal subjects and from SLE patients were fractionated into low and high density subpopulations. SLE patients were found to have an increased proportion of low density to high density non-T cells when compared to normal subjects. Although normal low-density non-T cells were highly enriched in AMLR stimulatory capacity, SLE low-density non-T cells induced minimal proliferation by autologous T cells. Brief incubation of SLE non-T cells with phorbol myristate acetate or formalin-treated Staphylococcus aureus resulted in marked augmentation of the capacity of those non-T cells to stimulate an AMLR, although the magnitude of the activated non-T cell-induced AMLR did not achieve that observed in normal subjects. No significant alterations in the expression of Ia molecules on the surface of the non-T cells were detected after in vitro activation. These experiments support the hypothesis that the impaired capacity of SLE T lymphocytes to proliferate in response to autologous non-T cells may in part represent a failure of SLE non-T cells to present an appropriate stimulus for the generation of a T cell response.
Introduction
Systemic lupus erythematosus (SLE)' is a disease characterized by the production of autoantibodies to various nuclear, cytoplasmic, and cell surface antigens (1) . It is manifest clinically by widespread tissue damage, at least in part attributable to those autoantibodies (1, 2) . Although antibodies of similar specificities may be made under certain circumstances in normal individuals (3) (4) (5) , control mechanisms presumably exist that limit the production of immunoglobulins with the potential for damage of autologous tissue. In patients with SLE, such regulatory controls have failed.
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We and others have previously described a marked deficiency in autologous mixed leukocyte reactivity (AMLR) in patients with SLE (6) (7) (8) (9) (10) . The AMLR is an in vitro system in which T lymphocytes proliferate in response to irradiated autologous non-T cells (1 1, 12) . It has been shown to generate suppressor activity (13, 14) . Thus, one possible consequence of an impaired AMLR in patients with SLE might be the defective generation of T suppressor cells and the factors responsible for inhibiting autoimmune reactivity.
The cellular basis of the impaired AMLR in patients with SLE has been studied by ourselves and others. Our studies involved MLR-identical twins discordant for SLE, and provided data in support of a defect in the capacity of non-T cells to stimulate autologous T cell proliferation (8) . Data from other laboratories have confirmed a non-T cell defect but have also documented impaired interleukin I (IL-1) and interleukin 2 (IL-2) production and depressed T lymphocyte responsiveness in the AMLR of SLE patients (9, 15) .
The present studies demonstrate that in contrast to untreated non-T cells from patients with SLE, which have little capacity to stimulate autologous T cells, in vitro-activated non-T cells stimulate vigorous autologous T cell proliferation. These data suggest that the impaired capacity of SLE T cells to proliferate in response to autologous non-T cells may result, in part, from a failure of the non-T cells to deliver the appropriate signal for the generation of an autologous T cell response.
Methods
Subjects. Nine control subjects were in good health and derived from laboratory personnel or volunteer blood donors to the New York Blood Center. 10 patients were studied, eight female and two male, who ranged in age from 21 to 58 yr. All cases had been followed in the clinic of The Rockefeller University Hospital by staff physicians and met the revised American Rheumatism Association criteria for the diagnosis of SLE (16) . Disease activity was assessed based on the presence of hematologic abnormalities (hemolytic anemia or platelet count < 60,000), fever, rash, arthritis, nephritis, serositis, or central nervous system involvement. Patients with none of these abnormalities at the time of study were termed inactive (0), those with one or two of these abnormalities were termed mildly active (+), and those with three or more of these abnormalities were termed active (++). The dose of immunosuppressive drug with which the patient was being treated at the time of study was recorded. Four patients were receiving no prednisone, two patients were receiving 10 mg of prednisone daily, and three patients were receiving >20 mg of prediiisone daily. We fractionated non-T cells, which had been depleted of some macrophages by 16-h adherence, from four normal subjects and from four SLE patients into low and high density subpopulations, quantitated the yield of low-and high-density non-T cells, and studied the AMLR stimulatory capacities of those cell preparations (Table I) . When the cell yields of low-and high-density non-T cells from the normal subjects and SLE patients were compared, approximately two-thirds of the normal non-T cells fell into the high density fraction, whereas approximately two-thirds of the non-T cells were in the low density fraction in the SLE patients. Whereas the low-density non-T fraction from the normal subjects was enriched in AMLR stimulatory capacity when compared with unfractionated non-T cells, the low-density [24] [25] [26] [27] . This effect is most evident with high density B cells (21).
We asked whether the AMLR in patients with SLE could be enhanced if an appropriate stimulus were presented. Non-T cells were incubated for 16 h with PMA, a tumor promoter that has the capacity to induce B cell differentiation, or with FSA, a relatively T-independent B cell mitogen. These cells were then exhaustively washed to remove the activators, irradiated, and cultured with autologous T cells (Table III) . Activated non-T cells from normal subjects stimulated three times as much (PMA) or two times as much (FSA) thymidine incorporation by autologous T cells when compared to the base-line AMLR. It should be noted that several subjects (normal subjects 1 and 3) had an augmented response when using one activator and not the other. In addition, the subjects with the most vigorous baseline AMLRs (subjects 4, 5, and 6) showed minimal augmentation, or a decrease, over their already excellent response after treatment of their non-T cells with the B cell activators. It may be that the non-T cells from these normal subjects had been activated in vivo and that in vitro treatment was less capable of increasing their AMLR stimulatory activity.
The AMLRs in patients with SLE were impaired when non-T cells were used to stimulate T cell proliferation. However, in vitro-activated non-T cells from SLE patients stimulated a vigorous AMLR. The mean thymidine incorporation induced by PMA-activated non-T cells was 29 times greater and that induced by FSA-activated non-T cells was 14 times greater than that stimulated by untreated non-T cells. As was true in normal subjects, there were several patients (subjects 5 and 10) who demonstrated an augmented AMLR after non-T cell activation with one mitogen, but not the other.
Experiments were performed in which varying numbers of untreated or PMA-activated stimulator cells were added to the AMLR cultures (Fig. 1) . Although the magnitude of the AMLR induced by PMA-activated non-T cells from three normal subjects was approximately twice that of the non-T PMA-stimulated AMLR observed in the three SLE patients studied, the dose-response pattern was similar in the two subject groups. The autologous T cell proliferation stimulated by 0.5 X 10 activated or untreated non-T cells from normal subjects or activated non-T cells from the SLE patients was about one-half that stimulated by 1 X 105 non-T cells. When the stimulator dose was diminished to 0.1 X l10 cells, the AMLR induced by activated or untreated non-T cells was not distinguishable from background T cell proliferation in either normal or SLE subjects.
It was possible that carryover of B cell activator into the AMLR cultures accounted for some of the T cell proliferation observed. determine the consistency of response pattern (Table IV) . The base-line AMLR was low in each case. Patient 7 demonstrated augmentation of the AMLR after activation with both PMA and FSA, and the degree of augmentation by FSA was equivalent on both occasions. Patient 5 showed no augmentation of the AMLR in response to FSA on either occasion although augmentation of the AMLR with PMA-pulsed non-T cells was noted. It is interesting that after tapering the prednisone dose from 30 mg daily to 10 mg daily, the PMA-induced AMLR was more dramatically enhanced, perhaps suggesting an inhibitory role of corticosteroids on non-T cell activation or on T cell response to activated non-T cells. Patient 2 had a greater response to PMA-activated than to FSA-activated non-T cells on both occasions. The pattern of response of T cells from SLE patients to autologous in vitro-activated non-T cells is, then, fairly consistent over time.
Percentage of Ia antigen-positive cells in activated and control non-T cell preparations. Cell surface Ia antigen on non-T cells is important in stimulating both autologous and anlogeneic T lymphocyte proliferation (18, 28). The percentage of peripheral blood non-T cells that bear Ia antigens has not been well studied in patients with SLE. It was possible that cells from such patients are deficient in Ia and acquire an increase in this surface molecule after incubation of the non-T cells with activating substances, as has been observed in a murine spleen cell system (29) . We determined the percentage of non-T cells that stained with an anti-Ia monoclonal antibody after a 16-h incubation with culture medium, PMA or FSA (Table  V) . Five normal subjects and four SLE patients did not significantly vary in the percentage of their non-T cells which stained with the anti-Ia antibody when assessed on FACS.
Neither PMA nor FSA activation resulted in an increase in the percent of Ia positive cells. FSA activation actually resulted in a slight decrease in the number of Ia-bearing non-T cells in the SLE patients. These results were confirmed with a second anti-Ia monoclonal antibody, SG171, which reacts mainly with DR determinants (data not shown). There was no consistent alteration in fluorescence intensity of anti-Ia staining of the activated compared with control non-T cells in either normal subjects or SLE patients (histograms on a representative patient, patient 1, are shown in Fig. 3 (30, 31) .
Discussion
These studies have examined the cellular basis of the impaired T-non-T cell interactions in patients with SLE. We had previously demonstrated a defect in the capacity of the non-T stimulator cell population to induce T lymphocyte proliferation in these patients (8) . Sakane et al. (7, 9) have also documented abnormalities of the non-T cell stimulators of the AMLR, but in addition, have detected a defect in T cell proliferative capacity in SLE. More recently, several laboratories have Results are expressed as mean percentage±standard error. documented impaired IL-I and IL-2 production in SLE patients (15, 32, 33) . Our experiments examined the capacity of non-T cells fractionated on Percoll gradients to stimulate an AMLR. High- (34) . The high-density non-T cell subpopulation from normal subjects is poor in AMLR stimulatory activity, whereas the low-density non-T cell subpopulation is highly enriched in such activity (19) (20) (21) (22) Much of the defect in IL-1 or IL-2 production that has been reported in patients with SLE (15, 32, 33) has presumably been overcome in our system, as activity of these lymphokines is a prerequisite for T cell proliferation in the AMLR (28) . Evidence has also been presented in murine models of SLE that demonstrates increased production of IL-2 by T cells when PMA is added to a concanavalin A-induced proliferation system (46, 47) . It was felt in these studies that stimulation of increased IL-l production by the PMA was unlikely to be responsible for the augmented IL-2 production observed. Preliminary experiments in our laboratory also suggest that the more vigorous AMLR seen after mitogen activation of non-T cells from patients with SLE is not attributable to increased IL-1 production. The defects in IL-2 production and response that have been documented by others may not, then, be accounted for entirely by primary abnormalities in the SLE T cell, but rather reflect, in part, the absence of a signal from non-T cells which helps to induce synthesis of lymphokines and possibly their receptors.
The mechanism by which in vitro-activated non-T cells stimulate augmented T cell proliferation has not been clarified. Ia molecules are essential for the induction of autologous T cell proliferation (18, 28). We wondered whether a deficiency in cell surface Ia on SLE non-T cells, which was corrected after in vitro activation, might account for our results. However, no difference was noted between normal and SLE non-T cells in terms of the percentage of cells staining with a monoclonal anti-Ia antibody or in the intensity of staining as assessed by histogram pattern on a cytofluorograph. After in vitro activation with mitogens, there was no consistent increase in these parameters in either normal subjects or in SLE patients. It is possible that further analysis of B cell subpopulations that uses antibodies reactive with various species of class II determinants might reveal specific abnormalities in the SLE cells, which could account for the impaired AMLR and its augmentation after in vitro non-T cell activation. Although the presence of Ia molecules on non-T cells may be necessary for the stimulation of the AMLR, they may not be sufficient for the generation of this in vitro response. Monoclonal antibodies reacting with B cell differentiation molecules have been produced in a number of laboratories (44, 48, 49) . Evaluation of normal and SLE non-T cells in the resting and activated state using such antibodies may help to define a B cell surface molecule, present on normal B cells but not on untreated SLE B cells, which is necessary for stimulation of autologous T cell proliferation.
Many investigators have presented data that suggest that SLE is characterized by primary defects in the B lymphocyte limb of the immune system (50, 51) . These defects are manifest as polyclonal B cell activation and secretion of autoantibodies of unusual and well-defined specificities. Studies of the T lymphocyte limb of the immune system have also demonstrated deficiencies, and we and others have postulated that impaired or failed regulation of B cells by abnormally functioning T cells may contribute to the overactivity of the B cells of SLE patients (8, 12, 51) . Our data suggest that at least some of the T cell abnormalities may not be intrinsic to those cells, but rather the result of the absence of a non-T cell signal required for autologous T cell proliferation. When SLE T lymphocytes are presented with a potent stimulator cell, they are capable of vigorous proliferative response. Further studies will be necessary to determine whether helper, suppressor, and cytotoxic activities are generated in the SLE T cells activated in this system.
